Hybrid immunity of the SARS-CoV-2 vaccine after the third doses in health workers

Authors

Keywords:

Hybrid immunity, SARS-CoV-2, COVID-19, neutralizing antibodies, vaccine, BNT162b2, BBIBP-CorV, healthcare workers

Abstract

Introduction: Hybrid immunity is the immune response of people
infected with COVID-19 who received the SARS-CoV-2 vaccine. This
combination is more powerful than the immunity that is generated
after vaccination or infection alone. Objective: To compare the hybrid
immunity of the SARS-CoV-2 vaccine after the third doses in healthcare
workers from a public hospital in Peru.
Objective: To compare the hybrid immunity of the SARS-CoV-2
vaccine after the third doses in healthcare workers from a public hospital
in Peru.
Material and Methods: A prospective observational cohort study
was conducted on health workers at the Carrion Hospital in Huancayo-
Peru; a total of 174 participants completed the study. Quantitative
monitoring of neutralizing antibodies (NAb) and immunoglobulin G (IgG)
was achieved after the first, second, and third doses of vaccination and
compared with the time of COVID-19 infection.
Results: The average age was 39 years. The average NAb was 3736
U in participants who became infected with COVID-19 after the second
vaccine, and with the third dose it was 3039 U. In the group not infected
with COVID-19, the average NAb production after the second dose was
1102U (p=0.009), and with the third vaccine, it was 2782U (p=0.685).
Conclusions: Hybrid immunity is significantly high after the second
dose, with a non-significant increase after the third dose of the vaccine

Downloads

Download data is not yet available.

References

1. Liu C, Yu X, Gao C, Zhang L, Zhai H, Hu, et al. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients. J Med Viro l[Internet]. 2021 [Citado 06/12/2022];93:2227–33. Disponible en: http://doi.org/10.1002/jmv.26646

2. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in healthcare workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet [Internet]. 2021[Citado 06/12/2022]; 397: 1725-35. Disponible en: https://doi.org/10.1016/S0140-

6736(21)00790-X

3. Levine-Tiefenbrun M, Yelin I, Alapi H, Katz R, Herzel E, Kuint J, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med [Internet]. 2021[Citado 06/12/2022];27:2108-10. Disponible en: https://doi.org/10.1038/s41591-021-01575-4

4. Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS- CoV-2 infection among health care workers in Israel. JAMA [Internet]. 2022 [Citado 06/12/2022];327:341-9. Disponible en: http://doi.org/10.1001/jama.2021.23641

5. Amirthalingam G, López G, Andrews N, Whitaker H, Gower C, Stowe J, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat. Commun [Internet]. 2021[Citado

06/12/2022];12: 7217. Disponible en: https://doi.org/10.1038/s41467-021-27410-5

6. Díaz-Lazo A, Montalvo R, Lazarte E, Aquino E. Caracterización clínica y epidemiológica de los pacientes con COVID-19 en un hospital situado en la altura. Horiz. Med [Internet]. 2021[Citado 06/12/2022];21(2):303. Disponible

en: http://dx.doi.org/10.24265/horizmed.2021.v21n2.09.

7. Casas Fischer R. Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech. Rev Esp Salud Publica [Internet]. 2021[Citado 06/12/2022];95:e202110141. Disponible en: http://doi.org/34690347

8. Ruiz-Romero A, Quijano-Castro FO, López-Romero R, Chavarría-Arriaga X, Torres M, Salcedo M. Immunity and COVID-19 vaccines. Revisiting the bases. Gac Med Mex [Internet]. 2022 [Citado 06/12/2022];158(5):317-22. Disponible en: http://doi.org/10.24875/GMM.M22000701

9. Alejandro M, Espejo J, Véliz D, Montalvo R. Comparison of the clinical characteristics of the first and second waves of COVID-19 in a public hospital in Peru. Boletín Malariologia y Salud Ambiental [Internet]. 2022 [Citado

06/12/2022];62(1):24-31. Disponible en: https://doi.org/10.52808/bmsa.7e5.621.004

10. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalization in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis [Internet]. 2022 [Citado 06/12/2022];22(6):781-90. Disponible en: http://doi.org/10.1016/S1473-3099(22)00143-8

11. Jia W, Pouwels B, Stoesser N, Matthews P, Diamond I, Studley R, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine [Internet]. 2022 [Citado 06/12/2022]; 28(5): 1072-82. Disponible en: https://doi.org/10.1038/s41591-022-01721-6

12. Hueda-Zavaleta M, Gómez J, Cáceres-Del Águila J, Muro-Rojo C, Nathalia D. Rodriguez-Morales A. Evaluation of the humoral immune response of a heterologous vaccination between BBIBP-CorV and BNT162b2 with a temporal separation of 7 months, in peruvian healthcare workers with and without a history of SARS-CoV-2 infection. Vaccines

[Internet]. 2022 [Citado 06/12/2022];10(4): 502. Disponible en: https://doi.org/10.3390/vaccines10040502

13. Vicenti I, Basso M, Dragoni F, Gatti F, Scaggiante R, Fiaschi L, et al. Comparable post-vaccination decay of neutralizing antibody response to wild-type and delta SARS-CoV-2 variant in healthcare workers recovered from mild or asymptomatic infection. Vaccines [Internet]. 2022 [Citado 06/12/2022];10(4):580. Disponible en: http://doi.org/10.3390/vaccines10040580

14. Lim SY, Park S, Kim JY, Kim S, Jee Y, Kim SH. Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural SARS-CoV-2 Infection (With/Without subsequent COVID-19 Vaccination) Versus 2-dose COVID-19 Vaccination. Clin Infect Dis [Internet]. 2022 [Citado 06/12/2022];10:435. Disponible en: http://doi.org/10.1093/cid/ciac435

15. Edelstein M, Beiruti KW, Ben-Amram H, Bar-Zeev N, Sussan C, Asulin H, et al. Antibody-mediated Immunogenicity against SARS-CoV-2 following priming, boosting and hybrid immunity: insights from 11 months of follow-up of a healthcare worker cohort in Israel, December 2020-October 2021. Clin Infect Dis [Internet]. 2022 [Citado 06/12/2022];12: 212. Disponible en: http://doi.org/10.1093/cid/ciac212

16. Rodda L, Morawski K, Pruner M, Fahning C, Howard N, Franko J, et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell [Internet]. 2022 [Citado 06/12/2022];185:1588. Disponible en: http://doi.

org/10.1016/j.cell.2022.03.018

17. Minervina A, Pogorelyy A, Kirk J, Crawford E, Allen, Chou C, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD81 T cells. Nat. Immunol [Internet]. 2022 [Citado 06/12/2022]; 23:781-90. Disponible en: https://doi.org/10.1038/s41590-022-01184-4

18. Goldblatt D. SARS-CoV-2: from herd immunity to hybrid immunity. Nat Rev Immunol [Internet]. 2022 [Citado 06/12/2022];22(6):333-34. Disponible en: http://doi.org/10.1038/s41577-022-00725-0

19. Bhattacharya M, Sharma AR, Dhama K, Agoramoorthy G, Chakraborty C. Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period. Int Immunopharmacol [Internet]. 2022 [Citado 06/12/2022];7:108. Disponible en: http://doi.org/10.1016/j.intimp.2022.108766

20. Claro F, Silva D, Bogado J, Rangel H, Waard J. Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V. Int J Infect Dis [Internet]. 2022 [Citado 06/12/2022];8: S1201. Disponible en: https://doi.org/10.1016/j.ijid.2022.06.008

21. Epsi N, Richard S, Lindholm D, Mende K, Ganesan A, Huprikar N, et al. EPICC COVID-19 Cohort Study Group.Understanding 'hybrid immunity': comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines. Clin Infect Dis [Internet]. 2022 [Citado 06/12/2022]; 24: 392. Disponible en: http://doi.org/10.1093/cid/ciac392

22. Otivo R, Almora-León K, Díaz-Lazo A, Beraun-Barrantes J, Tresierra-Ayala M. BBIBP-CorV/Sinopharm COVID-19 vaccine-induced humoral response in frontline workers. (2022) Boletin de Malariologia y Salud Ambiental [Internet]. 2022 [Citado 06/12/2022]; 62(3):436-43. Disponible en: https://doi.org/10.52808/bmsa.7e6.623.010

23. Martínek J, Tomášková H, Janošek J, Zelená H, Kloudová A, Mrázek J, et al. Immune Response 5-7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines. Viruses [Internet]. 2022 [Citado 06/12/2022];18:14(5). Disponible en: http://doi.org/10.3390/v14051086

24. Goldberg Y, Mandel M, Yinon M, Bar-On M. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med [Internet]. 2022 [Citado 06/12/2022];386(23):2201-12. Disponible en: http://doi.org/10.1056/

NEJMoa2118946

25. Wratil P, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med [Internet]. 2022 [Citado 06/12/2022];28(3):496-503. Disponible en: http://doi.org/10.1038/s41591-022-01715-4

Published

2024-02-13

How to Cite

1.
Montalvo R, Almora-León K, Diaz-Lazo A, Montalvo J, Tresierra-Ayala M, Aliaga-Córdova S. Hybrid immunity of the SARS-CoV-2 vaccine after the third doses in health workers. Rev haban cienc méd [Internet]. 2024 Feb. 13 [cited 2025 Jul. 3];22(5):e5170. Available from: https://revhabanera.sld.cu/index.php/rhab/article/view/5170

Issue

Section

Epidemiological and Salubrity Sciences